New study sheds light on antipsychotic safety during pregnancy and breastfeeding

NCT ID NCT05766007

First seen Feb 19, 2026 · Last updated Jun 23, 2026 · Updated 25 times

Summary

This completed observational study followed 168 pregnant or breastfeeding women with schizophrenia, psychosis, or mania who were already taking long-acting injectable antipsychotics. Researchers measured drug levels in the mother's blood, breastmilk, and the baby's blood to understand how pregnancy affects drug exposure. The goal is to help healthcare providers make informed decisions about using these medications during pregnancy and while breastfeeding.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PREGNANCY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Federal Medical Centre

    Makurdi, Benue State, Nigeria

  • Federal Neuropsychiatric Hospital

    Kaduna, Kaduna State, Nigeria

  • Federal Neuropsychiatric Hospital

    Yaba, Lagos, Nigeria

  • Neuropsychiatric Hospital

    Abeokuta, Ogun State, Nigeria

  • Neuropsychiatric Specialist Hospital

    Akure, Ondo State, Nigeria

  • Obafemi Awolowo University Teaching Hospital

    Ile-Ife, Osun State, Nigeria

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

long-acting injectable antipsychotics (Risperidone, Paliperidone palmitate, Fluphenazine decanoate, Flupenthixol decanoate, Zuclopenthixol decanoate)

What this could lead to

If successful, this study could help doctors better understand how to safely use long-acting antipsychotics in pregnant and breastfeeding women, improving care for both mother and baby.

What could go wrong

This is an observational study, not a treatment trial, so it won't directly test new therapies. Results may not apply to all women or all antipsychotics, and the small sample size limits how much we can conclude.

Conditions

The condition(s) this trial relates to.

Breast Feeding Mania psychotic disorder Psychotic Disorders schizophrenia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.